Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia | Zendy

Thomas M. File | Zendy; Donald E. Low | Zendy; Paul B. Eckburg | Zendy; George H. Talbot | Zendy; H. David Friedland | Zendy; Jon Lee | Zendy; Lily Llorens | Zendy; Ian A. Critchley | Zendy; Dirk Thye | Zendy

Open Access

Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia

Author(s) -

Thomas M. File,

Donald E. Low,

Paul B. Eckburg,

George H. Talbot,

H. David Friedland,

Jon Lee,

Lily Llorens,

Ian A. Critchley,

Dirk Thye

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/657313

Subject(s) - medicine , ceftriaxone , community acquired pneumonia , cephalosporin , randomized controlled trial , adverse effect , pneumonia , population , clinical trial , surgery , antibiotics , microbiology and biotechnology , environmental health , biology

Ceftaroline, the active form of ceftaroline fosamil, is a broad-spectrum cephalosporin with bactericidal activity against pathogens causing community-acquired pneumonia (CAP), including Streptococcus pneumoniae. Ceftaroline was evaluated for the treatment of CAP in 2 randomized, double-blind, multicenter trials: Ceftaroline Community Acquired Pneumonia Trial versus Ceftriaxone in Hospitalized Patients (FOCUS) 1 and FOCUS 2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research